Stockscreener 앱 받기
4.48
0.67%
0.00
Vanda Pharmaceuticals Inc 주식(VNDA)의 최신 뉴스
Vanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated at StockNews.com - MarketBeat
D.C. biotech Vanda Pharmaceuticals acquires AnaptysBio’s drug for rare skin disorder - The Business Journals
HC Wainwright Reaffirms Buy Rating for Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat
Vanda and AnaptysBio link for generalised pustular psoriasis therapy - Pharmaceutical Technology
Vanda Pharmaceuticals and Anaptys sign license agreement for imsidolimab - MSN
Vanda, Anaptys Join on Development Pact - Baystreet.ca
AnaptysBio Partners with Vanda for Imsidolimab Development - TipRanks
Vanda Pharmaceuticals, AnaptysBio Sign Global License Agreement for Imsidolimab - Marketscreener.com
Vanda Pharmaceuticals and AnaptysBio to develop and market imsidolimab - TipRanks
Breakthrough GPP Treatment Deal: Vanda Secures Phase 3-Ready Rare Disease Drug for $15M Upfront - StockTitan
Indo-Asian News Service - IANS India Pvt Ltd
Vanda Pharmaceuticals (VNDA) to Release Quarterly Earnings on Wednesday - MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Buy Rating from HC Wainwright - MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com - MarketBeat
H.C. Wainwright maintains $18 target on Vanda Pharmaceuticals stock - MSN
Vanda Pharmaceuticals seeks FDA nod for motion sickness drug - MSN
H.C. Wainwright maintains $18 target on Vanda Pharmaceuticals stock By Investing.com - Investing.com Canada
Washington D.C. Pharma Co. Receives FDA Acceptance - Streetwise Reports
US Exchange Penny Stocks To Watch In January 2025 - Simply Wall St
A Glimpse Into The Expert Outlook On Vanda Pharma Through 4 Analysts - Benzinga
D.C.'s Vanda Pharmaceuticals battling FDA on multiple fronts - The Business Journals
Vanda granted hearing to discuss FDA rejection of application for tradipitant - MSN
Vanda Pharmaceuticals seeks FDA nod for motion sickness drug By Investing.com - Investing.com South Africa
Vanda granted hearing to discuss FDA rejection of application for tradipitant ( - Seeking Alpha
Vanda Pharmaceuticals Files New Drug Application - TipRanks
Vanda Pharmaceuticals accepts FDA opportunity for a hearing in tradipitant NDA - TipRanks
Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis - PR Newswire
Vanda Loses US Trade Secrets Battle Over Fanapt And Hetlioz Generics - News & Insights
US Claims Court rules Vanda’s trade secrets not so secret - BioWorld Online
Vanda Loses US Trade Secrets Battle On Fanapt And Hetlioz ANDA Products - News & Insights
Equities Analysts Issue Forecasts for VNDA FY2025 Earnings - MarketBeat
Vanda Loses Takings Clause Arguments In Trade Secret Fight - Law360
Vanda Pharmaceuticals (NASDAQ:VNDA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by Analysts at StockNews.com - MarketBeat
Vanda asserts FDA review of tradipitant was flawed - MSN
Insomnia Market Overall Study Report 2025-2032 | Vanda - openPR
Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharma, Ironwood Pharma, Takeda, Neurogastrx, Inc, PTC Thera - The Globe and Mail
FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate - Yahoo Finance
Pugilistic Vanda Collects Another NOOH As US FDA Defends Tradipitant Turndown - News & Insights
DC Circuit Skeptical of FDA Rejection of Vanda’s Jet Lag Drug - Bloomberg Law
High Court Rejects Vanda Suit Over Medicaid Drug Definition - Bloomberg Law
Vanda’s Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review - BioSpace
Vanda Pharmaceuticals Highlights Issues in Gastroparesis Treatment Application Review in Letter to FDA Commissioner - Marketscreener.com
Vanda Pharmaceuticals Challenges FDA Over Gastroparesis Drug Rejection in Open Letter - StockTitan
Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now? - Yahoo Finance
StockNews.com Initiates Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat
0.40%
0.58%
자본화:
|
볼륨(24시간):